Patents by Inventor Miles Stuart Congreve

Miles Stuart Congreve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11999745
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and/or M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1): and salts thereof.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: June 4, 2024
    Assignees: Heptares Therapeutics Limited, Allergan Pharmaceuticals Therapeutics International Limited
    Inventors: Charlotte Fieldhouse, Miles Stuart Congreve
  • Patent number: 11987648
    Abstract: The disclosures herein relate to novel compounds of formula (1):(1) and salts thereof, wherein W, X, Y, Z, m, n, q, R1, R2, R3, R4, R5 and R6 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with somatostatin receptors.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: May 21, 2024
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Conor Scully, Rebecca Paul, Andrea Bortolato
  • Publication number: 20240092754
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
    Type: Application
    Filed: March 24, 2023
    Publication date: March 21, 2024
    Inventors: John Andrew CHRISTOPHER, Miles Stuart CONGREVE, Sarah Joanne AVES, Benjamin Gerald TEHAN
  • Publication number: 20240083845
    Abstract: The disclosures herein relate to compounds of Formula (1?): or a salt thereof, wherein A, Q, X, Z, L, R2, R3 and R9 are defined herein, and their use in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro.
    Type: Application
    Filed: December 20, 2021
    Publication date: March 14, 2024
    Applicant: HEPTARES THERAPEUTICS LIMITED
    Inventors: Miles Stuart CONGREVE, John Andrew CHRISTOPHER, Mark PICKWORTH, Chris DE GRAAF, Alicia Perez HIGUERUELO, Jonathan Stephen MASON, Santosh S. KULKARNI
  • Publication number: 20240043428
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: December 21, 2022
    Publication date: February 8, 2024
    Inventors: Gilbert BESONG, Christopher Thomas BRAIN, Clinton A. BROOKS, Miles Stuart CONGREVE, Claudio DAGOSTIN, Guo HE, Ying HOU, Steven HOWARD, Yue LI, Yipin LU, Paul MORTENSON, Troy SMITH, Moo Je SUNG, Steven WOODHEAD, Wojciech WRONA, Bharat LAGU
  • Patent number: 11834407
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: December 5, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Mark Pickworth, Benjamin Gerald Tehan
  • Publication number: 20230382949
    Abstract: The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein Q, X, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, AA10, AA11, AA12, AA13, R1 R2 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Apelin receptors.
    Type: Application
    Filed: October 12, 2021
    Publication date: November 30, 2023
    Applicant: HEPTARES THERAPEUTICS LIMITED
    Inventors: Giles Albert BROWN, Miles Stuart CONGREVE, Conor SCULLY, Rebecca PAUL
  • Publication number: 20230382950
    Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein Q, X, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, R1, R2 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with apelin receptors.
    Type: Application
    Filed: October 12, 2021
    Publication date: November 30, 2023
    Applicant: HEPTARES THERAPEUTICS LIMITED
    Inventors: Giles Albert BROWN, Miles Stuart CONGREVE, Conor SCULLY, Rebecca PAUL
  • Patent number: 11793817
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R1-R6 are as defined herein.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: October 24, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: Miles Stuart Congreve, Giles Albert Brown, Julie Elaine Cansfield, Benjamin Gerald Tehan
  • Publication number: 20230331720
    Abstract: The present disclosure relates to compounds of Formula (I?): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 19, 2023
    Inventors: Bruce LEFKER, Gordon SAXTY, Karl GIBSON, Mark PICKWORTH, Matthew SPENDIFF, Miles Stuart CONGREVE, Paul HUMPHRIES
  • Publication number: 20230295260
    Abstract: The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein Q, W, X, Y, Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, LysR, R 1, R2 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide (GLP) receptors.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 21, 2023
    Applicant: HEPTARES THERAPEUTICS LIMITED
    Inventors: Giles Albert BROWN, Miles Stuart CONGREVE, Conor SCULLY, Rebecca PAUL, Andrea BORTOLATO
  • Publication number: 20230279053
    Abstract: The disclosures herein relate to novel internally cyclic peptide compounds of formula (1) and salts thereof, wherein R1, AA1, AA2, LysR, X and Y are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide-1 (GLP-1) receptors.
    Type: Application
    Filed: July 27, 2021
    Publication date: September 7, 2023
    Applicant: HEPTARES THERAPEUTICS LIMITED
    Inventors: Giles Albert BROWN, Miles Stuart CONGREVE, Conor SCULLY
  • Publication number: 20230271964
    Abstract: Described herein are triazalone compounds of Formula (I) and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.
    Type: Application
    Filed: March 25, 2021
    Publication date: August 31, 2023
    Inventors: Giles Albert Brown, Christine Mary Richardson, Miles Stuart Congreve, Rebecca Paul, Stephen Philippe Andrews, Jonathan Stephen Mason
  • Patent number: 11680053
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: June 20, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Aves, Benjamin Gerald Tehan
  • Publication number: 20230167094
    Abstract: The disclosure herein relates to azetidinylpyrimidin-2-amine derivatives, their use as Histamine H4 receptor antagonists and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 1, 2023
    Applicant: Heptares Therapeutics Limited
    Inventors: Miles Stuart CONGREVE, Charlotte FIELDHOUSE, Nigel Alan SWAIN, Mark PICKWORTH, Duncan Robert HANNAH
  • Publication number: 20230146483
    Abstract: Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.
    Type: Application
    Filed: March 25, 2021
    Publication date: May 11, 2023
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Christine Mary Richardson, Rebecca Paul, Stephen Philippe Andrews, Jonathan Stephen Mason, Francesca Deflorian, Nigel Alan Swain
  • Publication number: 20230146796
    Abstract: Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.
    Type: Application
    Filed: March 25, 2021
    Publication date: May 11, 2023
    Applicant: ASTRAZENECA AB
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Francesca Deflorian, Nigel Alan Swain
  • Patent number: 11584732
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: February 21, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Aves, Benjamin Gerald Tehan
  • Publication number: 20230021177
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more hetermatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic
    Type: Application
    Filed: April 23, 2021
    Publication date: January 19, 2023
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Publication number: 20220411364
    Abstract: The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.
    Type: Application
    Filed: October 9, 2020
    Publication date: December 29, 2022
    Inventors: Miles Stuart Congreve, Nigel Alan Swain, Benjamin Whitehurst